---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-26-000003"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2026-01-05T23:59:59+00:00"
generated_at: "2026-05-16T11:40:46.125455+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Moderna projects 2025 revenue $1.6-2.0B, targets up to 10% growth in 2026

## Summary
- 2025 revenue guidance of $1.6-2.0B; cash costs beat commitments by nearly $1B.
- mNEXSPIKE captured ~24% of U.S. retail COVID shots and ~33% of 65+ segment.
- Secured $1.5B five-year term loan; GAAP opex to fall below $5.5B in 2025 from $7.2B in 2024.
- Cash cost target: ~$4.2B in 2026 and $3.5-3.9B in 2027; cash breakeven targeted in 2028.
- Pipeline: Phase 3 flu efficacy positive; intismeran Phase 2b data and nine oncology readouts expected.

## SEC filing metadata
- accession: 0001682852-26-000003
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2026-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000003/0001682852-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000003/mrna-20260105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-26-000003
- JSON: https://secwatch.observer/filing/0001682852-26-000003.json
- Plain text: https://secwatch.observer/filing/0001682852-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.